Welcome to our dedicated page for ProMIS Neurosciences SEC filings (Ticker: PMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ProMIS Neurosciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ProMIS Neurosciences's regulatory disclosures and financial reporting.
Jeremy M. Sclar 2012 Irrevocable Family Trust filed an Initial Statement of Beneficial Ownership reporting direct ownership of 1,617,437 common shares of ProMIS Neurosciences, Inc. (PMN) and multiple warrants convertible into additional common shares. Reported derivative holdings include 26,217 warrants (exercise $7.50, exp. 04/11/2028), 664,894 warrants (exercise $1.75, exp. 02/24/2029), and three tranches of purchase warrants from a July 31, 2024 private placement totaling 2,093,022 underlying shares across Tranche A, B and C (exercise prices of $2.02 for A and B, $2.50 for C; various exercisability and expiry conditions). The Form 3 identifies the reporting person as a Director and the filing is made by one reporting person.
ProMIS Neurosciences Inc. updated the employment terms of its Chief Scientific Officer, Dr. Neil Cashman, through an Amended and Restated Employment Agreement effective September 26, 2025. Dr. Cashman will remain on the board and continue in his role as Chief Scientific Officer.
The amended agreement sets an annual base salary of $500,000 CAD and an annual discretionary bonus targeted at 35% of base salary. Dr. Cashman received an option to purchase 165,000 common shares at Fair Market Value on the grant date, vesting 25% after one year and the balance in equal monthly installments over thirty-six months.
He is entitled to 9 months of salary and continued benefits if terminated without cause, and to 9 months of salary, accelerated vesting of time-based equity awards, and continued benefits in connection with a change in control. The company states there are no family relationships or related-party transactions requiring disclosure.
Neil K. Warma, Chief Executive Officer and Director of ProMIS Neurosciences Inc. (PMN), reported a Section 16 transaction on Form 4 showing the acquisition of derivative securities on 09/22/2025. The filing records an award of 600,000 stock options with an exercise price of $0.45 that expire on 09/22/2035. Following the reported transaction, Mr. Warma beneficially owns 600,000 options directly. The options vest with 25% vesting on September 1, 2026 and the remainder vesting ratably over the following 36 months. The Form 4 was signed by an attorney-in-fact on 09/24/2025.
Insider option grant reported for ProMIS Neurosciences (PMN). Max A. Milbury, listed as Principal Accounting Officer, was granted an option to purchase 60,000 common shares at an exercise price of $0.45 per share on 09/22/2025. The option has an expiration date of 09/22/2035. Vesting: 25% vests on 09/01/2026, with the remainder vesting ratably over the next 36 months. The filing was signed 09/24/2025 and is a single-person Form 4.
ProMIS Neurosciences (PMN) reported an insider option grant to Neil Cashman, who serves as a director and Chief Scientific Officer. The report shows an option to purchase 165,000 common shares with a $0.45 exercise price, granted with a transaction date of 09/22/2025. The option becomes exercisable on 09/22/2025 and expires on 09/22/2035. Vesting is specified: 25% vests on September 1, 2026 and the remainder vests ratably over the following 36 months. The Form 4 was signed by an attorney-in-fact for Mr. Cashman on 09/24/2025. The filing reflects a non-derivative underlying position of 165,000 common shares after the reported transaction.
ProMIS Neurosciences reported an insider equity award: Chief Development Officer Johanne Kaplan was granted an option to buy 165,000 common shares at a $0.45 exercise price. The option was granted on 09/22/2025, becomes exercisable beginning 09/22/2025, and expires on 09/22/2035. Under the disclosed vesting schedule, 25% of the option vests on 09/01/2026 and the remaining portion vests ratably over the following 36 months. The Form 4 was signed on behalf of Ms. Kaplan on 09/24/2025 by an attorney-in-fact.
Larry Douglas Altstiel, Chief Medical Officer and director of ProMIS Neurosciences Inc. (PMN), was granted stock options on 09/22/2025. The Form 4 reports an award of 165,000 option rights to purchase common shares at an exercise price of $0.45 per share. The instrument is an option with an expiration tied to 09/22/2035. The reporting person beneficially owns 165,000 shares following the transaction and these holdings are listed as direct ownership. Per the filing, 25% of the option shares vest on September 1, 2026 and the remainder vests ratably over the following 36 months. The Form 4 was signed by an attorney-in-fact on 09/24/2025.
ProMIS Neurosciences Inc. is soliciting votes for a virtual Special Meeting for holders of record as of September 26, 2025. The meeting will be entirely online at www.virtualshareholdermeeting.com/PMN2025SM and proxy materials are available at www.proxyvote.com and www.sedarplus.ca. The principal proposal is a Share Consolidation (reverse split) requiring approval by 66 2/3% of votes cast. The board unanimously recommends voting FOR the consolidation. The filing describes potential effects on per-share metrics, authorized shares, anti-takeover mechanisms, and U.S. and Canadian tax considerations. Broker voting and voting procedures for street-name holders are explained.
Jeremy M. Sclar, a director of ProMIS Neurosciences Inc. (PMN), reported multiple transactions in July 2025 that materially changed his beneficial holdings. On July 25, 2025 the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A, 697,674 Tranche B and 697,674 Tranche C purchase warrants, each converting to one common share. Although original exercise prices ranged from $2.02 to $2.50, the exercises were completed at $0.83518 per share following an offer accepted by the issuer. The JS Trust subsequently acquired, on July 29, 2025, a warrant to purchase 3,139,533 common shares exercisable at $1.25 and expiring five years after issuance. The report also shows a disposition of 65,000 common shares held through Crocker Mountain LLC.
ProMIS Neurosciences, Inc. files a shelf registration prospectus describing the offer and sale of securities and incorporating by reference multiple SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Forms 10-Q and 8-Ks. The prospectus highlights forward-looking statements and extensive risk factors, including liquidity and going-concern risks, regulatory, patent and market-competition risks, and operational impacts from global events. Corporate actions disclosed include a 60:1 reverse share split effective June 28, 2022 (all historic share numbers adjusted), a continuance to Ontario corporate law effective July 13, 2023, and listing of common shares on Nasdaq under the symbol PMN. The company also cites exemptions under the JOBS Act and limited executive compensation and auditor-attestation disclosures.